Abstract:CONTEXT:There is concern that the widespread use of antiretroviral drugs to treat human immunodeficiency virus 1 (HIV-1) infection may result in the increased transmission of drug-resistant virus.OBJECTIVE:To determine the prevalence of drug resistance-conferring mutations and phenotypic resistance to antiretroviral agents in a cohort of individuals newly infected with HIV-1.DESIGN:Case series with genetic analyses of the HIV-1 plasma-derived pol gene using reverse transcriptase polymerase chain reaction followed by direct sequencing of polymerase chain reaction products. Phenotypic analysis was performed with a recombinant virus assay.SETTING AND PATIENTS:Eighty individuals referred, on average, 1.7 months after infection with HIV-1 to the Aaron Diamond AIDS Research Center between July 1995 and April 1999. Subjects were from large urban areas (65 from New York, NY; 11 from Los Angeles, Calif); 60 (75%) were white, and 75 (93.8%) were homosexual men.MAIN OUTCOME MEASURES:Prevalence of known resistance-conferring genotypes and reduced susceptibility to individual antiviral agents by phenotype.RESULTS:Thirteen individuals (16.3%) had genotypes associated with drug resistance to any antiretroviral agent. Virus with known resistance-conferring mutations to any nucleoside reverse transcriptase inhibitors was found in 10 individuals, to any nonnucleoside reverse transcriptase inhibitors in 6 subjects, and to any protease inhibitors in 2 cases. Multidrug-resistant virus was identified in 3 individuals (3.8%). Extensive polymorphism in the protease gene was identified. Interpretation of genotypes and phenotypes was concordant in 57 (85%) of the 67 cases in which both studies were performed.CONCLUSION:The prevalence of HIV-1 variants with known resistance-conferring genotypes to any antiretroviral agent in this cohort of 80 newly infected individuals is 16.3%. These data support expanded use of resistance testing in the setting of primary HIV-1 infection. Clinical trials should be initiated to establish whether therapy guided by resistance testing, compared with the use of empirical triple combination antiretroviral therapy, provides additional virological and immunological benefit when treating primary HIV-1 infection. Further efforts to expand the study of transmission of drug-resistant HIV-1 variants, particularly in cohorts with different epidemiological profiles, are indicated.

Resistance-associated Mutations to HCV Protease Inhibitors Naturally Pre-Existed in HIV/HCV Coinfected, Treatment-Naïve Patients.

Naturally Occurring Hepatitis C Virus Protease Inhibitors Resistance-Associated Mutations among Chronic Hepatitis C Genotype 1b Patients with or Without HIV Co-Infection.

The Central Nervous System is a Potential Reservoir and Possible Origin of Drug Resistance in Hepatitis B Infection

[Sequence Detection of HBV-DNA P and C Region in HIV/HBV Superinfection Subjects with Drug Resistance to HAART].

Naturally occurring HCV resistance to telaprevir and boceprevir in previous paid blood donors with HCV/HIV-1 co-infection

Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design.

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents

World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients

Natural resistance mutations to direct-acting antiviral agents in interferon/ribavirin treatment-experienced and treatment-naive patients with chronic hepatitis C in Beijing, China

Prevalence of HCV Resistance-Associated Substitutions amongTreatment FailurePatients receiving Direct-Acting Antiviral Agents.

Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy

Novel Imino Sugars Potently Inhibit HCV Virion Secretion by Targeting Cellular Endoplasmic Reticulum Α-Glucosidases

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.

Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors

Gene Mutations of Human Immunodeficiency Virus Drug Resistance from Men Who Have Sex with Men in Shanghai,2013

Looking at the Molecular Target of NS5A Inhibitors throughout a Population Highly Affected with Hepatitis C Virus

Prevalence of drug-resistant human immunodeficiency virus type 1 in antiretroviral-treated patients of China

HIV-1 Drug Resistance in Newly Infected Individuals

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis